Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.09.2023 | Case report

Tofacitinib

Acute appendicitis: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Weber F, et al. Manifestation of acute appendicitis as known but paradox visceral side effect of ulcerative colitis anti-inflammatory therapy with januskinase-inhibitor Tofacitinib (Xeljanz TM). Pathology Research and Practice 248: Aug 2023. Available from: URL: http://doi.org/10.1016/j.prp.2023.154333 [abstract] Weber F, et al. Manifestation of acute appendicitis as known but paradox visceral side effect of ulcerative colitis anti-inflammatory therapy with januskinase-inhibitor Tofacitinib (Xeljanz TM). Pathology Research and Practice 248: Aug 2023. Available from: URL: http://​doi.​org/​10.​1016/​j.​prp.​2023.​154333 [abstract]
Metadaten
Titel
Tofacitinib
Acute appendicitis: case report
Publikationsdatum
01.09.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-45993-6

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Nivolumab

Case report

Antineoplastics